Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
$15.25
$15.23
$4.81
$15.37
$753.61M-0.06974,748 shs600 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$9.16
+3.2%
$9.24
$2.20
$12.78
$243.22M-0.63190,661 shs10,445 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$137.46
-1.0%
$140.66
$122.80
$219.34
$4.01B0.66287,519 shs418,984 shs
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$0.36
$0.05
$11.78
$5.07M1.2434.54 million shs23.06 million shs
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$0.54
+0.1%
$0.56
$0.30
$3.18
$126.12M1.29.01 million shs2.23 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
0.00%-2.29%+10.66%+34.68%+129.34%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
0.00%+4.85%+9.30%-22.97%-24.37%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
0.00%0.00%0.00%0.00%0.00%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
0.00%+18.23%+19.93%-18.05%+50.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
3.7019 of 5 stars
4.43.00.00.02.72.50.6
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
4.5877 of 5 stars
3.51.00.04.73.12.51.9
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
2.8189 of 5 stars
3.34.00.00.03.10.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
0.00
N/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.80
Moderate Buy$14.7561.03% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$211.1353.59% Upside
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
0.00
N/AN/AN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
2.67
Moderate Buy$4.50731.33% Upside

Current Analyst Ratings Breakdown

Latest NSTG, AERI, SGMO, DBVT, and KRYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$21.00
6/24/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00
6/24/2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/29/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell$7.25
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.00
5/16/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.00
5/14/2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$9.00 ➝ $5.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$195.00 ➝ $189.00
5/7/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$219.00 ➝ $219.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
$194.13M3.88N/AN/A($3.32) per share-4.59
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$4.15M60.46N/AN/A$1.42 per share6.45
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$290.52M13.67$4.59 per share29.95$32.90 per share4.18
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$127.26M0.00N/AN/A$0.98 per share0.00
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$57.80M2.18N/AN/A$0.11 per share4.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
-$74.81M-$0.77N/AN/AN/A-17.09%N/A-2.00%N/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$113.92M-$4.92N/AN/AN/A-3,249.99%-278.24%-140.54%7/29/2025 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$89.16M$4.1633.0413.64N/A37.17%14.64%13.28%8/4/2025 (Estimated)
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
-$159.54M-$3.53N/AN/AN/A-102.44%-548.25%-53.79%N/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
-$97.94M-$0.39N/AN/AN/A-124.61%-345.98%-79.86%8/5/2025 (Estimated)

Latest NSTG, AERI, SGMO, DBVT, and KRYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
-$0.11-$0.14-$0.03-$0.14$7.90 million$6.44 million
5/6/2025Q1 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.38$1.20-$0.18$1.20$98.66 million$88.18 million
4/11/2025Q4 2024
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A-$1.10N/A-$1.10N/A$0.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/AN/AN/AN/AN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/A
2.27
1.92
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
0.72
0.72
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.65
9.27
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/A
2.73
2.02
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/A
0.76
0.76
CompanyEmployeesShares OutstandingFree FloatOptionable
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
37649.42 million47.22 millionOptionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
8027.39 million27.00 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21028.90 million24.94 millionOptionable
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
55048.12 million46.63 millionOptionable
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
480233.17 million223.61 millionOptionable

Recent News About These Companies

Sangamo cues up Fabry gene therapy filing on STAAR data

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aerie Pharmaceuticals stock logo

Aerie Pharmaceuticals NASDAQ:AERI

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$9.16 +0.28 (+3.15%)
As of 03:59 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$137.46 -1.42 (-1.02%)
As of 04:00 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

NanoString Technologies stock logo

NanoString Technologies NASDAQ:NSTG

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Sangamo Therapeutics stock logo

Sangamo Therapeutics NASDAQ:SGMO

$0.54 +0.00 (+0.07%)
As of 04:00 PM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.